Abstract. Tumor size indicates the extent of cell proliferation in most cases of colorectal cancer (CRC), although there are some advanced small tumors with metastases. Lymph node metastasis is a significant factor that greatly impacts disease prognosis in CRC cases. The underlying factors that cause lymph node metastasis in CRC cells are not fully understood. We investigated the mechanism that might induce CRC metastasis by focusing on smaller sized (<2 cm) invasive tumors. We carried out gene expression array analysis for CRC cases; group 1 consisted of 6 cases with tumors <2 cm with metastases, and group 2 consisted of 65 cases with tumors >2 cm without metastases. Results were validated using gene expression array data from an additional 77 cases and another bulk case set of 172 cases. Gene Ontology and pathway analysis using microarray data revealed that anti-apoptotic activity had a crucial role in CRC metastasis. High mobility group A1 (HMGA1) was identified as a biomarker for poor prognosis and metastasis formation. HMGA1 expression levels were higher in lymph node-positive cases than in lymph node-negative cases, even in subgroup analysis of submucosal invasive cases. The present study strongly supports the clinical significance of HMGA1 expression as a predictive indicator of lymph node metastasis in CRC cases, even in submucosal invasive cases which could be cured by local resection.
Introduction
Although tumor size is not a factor in deciding tumor stage according to TNM classification of the UICC (Union for International Cancer Control) or the Japanese classification of colorectal carcinoma, tumor size is generally considered to be an indicator of proliferation potency and thereby malignancy. There are some colorectal cancer (CRC) cases with small tumors and metastasis, and, conversely, tumors of large size without metastasis. Such small tumors with the capability to metastasize are estimated to have a tendency of vertical invasion and vascular invasion, and these tumors often have a high malignancy grade that induces lymph node or distant metastasis. Therefore, we hypothesized that such small but advanced cancer might have distinctive characteristics which are involved in cancer metastasis, particularly for the lymph nodes.
Several researchers have studied metastasis-regulating factors (1) (2) (3) . Gene expression arrays using in vivo models (2) and clinical samples (1, 2) and proteomics analysis using clinical samples (3) have all been carried out, and certain genes and pathways have been identified as biomarkers for CRC metastasis. There is some discord between past reports, however, therefore the underlying factors that cause tumor metastasis remain to be fully understood.
Lymph node metastasis is a significant factor that has an impact on disease prognosis in CRC cases. While patients without metastasis can mostly be cured by resection of the primary tumor and thus have a 5-year survival rate exceeding 80%, patients with lymph node metastasis often experience a relapse and therefore have a 5-year survival rate of <50% (4, 5) . We have, thus, focused on identifying biomarkers for CRC lymph node metastasis, which will be helpful in determining treatment strategy and may provide further insight into tumor biology.
In the present study, we investigated significant factors for cancer metastasis, particularly lymph node metastasis, by using gene expression microarray analysis of small tumors with metastases and large tumors without metastases.
Microarray analysis reveals that high mobility group A1
is involved in colorectal cancer metastasis Laser microdissection. Tissue samples were microdissected using the LMD6000 Laser microdissection system (Leica Laser Microdissection System; Leica Microsystems, Wetzlar, Germany) as previously described (6) . For laser microdissection, five micron frozen sections were fixed in 70% ethanol for 30 sec, stained with hematoxylin and eosin, and dehydrated for 5 sec each in 70, 95 and 100% ethanol. Sections were air-dried, then microdissected with the LMD system. Target cells were excised, at least 100 cells per section, and bound to the transfer film. Then, total RNA was extracted. Statistical analysis. For gene expression array analysis, the differences between groups were estimated using the Student's t-test after expression signals were calculated by log2-transformation of the normalized data. Differentially expressed genes were detected by using the P-value, fold-change value and q-value. All differences were considered statistically significant at the level of P<0.05 or false discovery rate (FDR) P<0.05. Data from RT-PCR analyses were analyzed using JMP 5 software (JMP, Cary, NC, USA). Overall survival rates were calculated actuarially according to the Kaplan-Meier method and were measured from the day of surgery. Differences between groups were estimated using the Chi-square test, Student's t-test, repeated-measures ANOVA and log-rank test. A probability level of 0.05 was selected for statistical significance.
Results
A total of 1662 genes are differently expressed between the two groups. We first selected 71 cases (set 1) and subdivided them into two groups. Group 1 consisted of 6 colorectal cancers which were <2 cm in size and had metastasis; group 2 consisted of 65 cases with tumors >2 cm in size that lacked metastasis (Table I) . A significant difference in expression level (FDR <0.05) between the two groups was found in Average score which were significantly differently regulated in group 1. Results are shown in Table II . The Gene Ontologies 'NF-κB binding', 'negative regulation of MAP kinase activity', 'regulation of epidermal growth factor receptor signaling pathway' and 'apoptotic process' were significantly enriched in this set of genes. We performed pathway analysis to identify the pathways which actually determine the character of these tumors. A summary result of the analysis is shown in Table III . No significant difference of activation level was found in pathways associated with oncogenes such as RAS and cell-cycle genes. However, we identified significant inactivation of genes involved in the WNT signaling pathway and several apoptosis-related pathways in group 1. Inactivation of WNT signaling seemed to be associated with the smaller tumor size of group 1. The inactivation of apoptosis in group 1 tumors may contribute to their ability to form metastasis sites.
We also carried out gene expression array for 77 more cases for further analysis. Using the microarray results for all 148 CRC cases, we investigated the correlation of the above 1662 genes with prognosis and the following clinicopathological factors: overall survival, disease-free survival, tumor size, histological grade, serosal invasion, lymph node metastasis, lymphatic invasion, venous invasion, peritoneal dissemination, liver metastasis and distant metastasis. Twenty-three genes, whose count of significant factors was over three, were extracted (Table IV) . We focused on HMGA1 as it is reported to have a critical role in both neoplastic transformation and the inactivation of p53's apoptotic function (10) . HMGA1 had an FDR <0.05 in the analysis described above for the 1662 identified genes (data not shown).
HMGA1 mRNA expression is a robust indicator of lymph node metastasis and patient prognosis. HMGA1 mRNA expression in the bulk 172 tumor tissues and corresponding normal tissues (case set 3) was examined by qRT-PCR to validate the clinical significance of HMGA1 expression in CRC cases. HMGA1 mRNA levels in cancerous tissues were significantly higher than those in non-cancerous tissues (P<0.0001; Fig. 1A ). The significant difference was maintained in the analysis of small sized tumors (<2 cm, P<0.0001; Fig. 1B) .
Next, we divided the 172 patients with CRC into a high HMGA1 expression group (n=86) and a low HMGA1 expression group (n=86), classified as having expression levels higher or lower than the median value, respectively. Clinicopathological factors were compared between the high and low HMGA1 mRNA expression groups (Table V) . The high HMGA1 expression group showed higher risk for lymph node metastasis. Univariate analysis of lymph node metastasis revealed that the relative level of HMGA1 expression was a lymph node metastasis risk factor similar to serosal invasion, lymphatic invasion, venous invasion and liver metastasis (Table VI) . Variables with a value of P<0.05 were selected for multivariate analysis. Multivariate analysis showed that HMGA1 expression was an independent lymph node metastasis risk factor in patients with CRC (relative risk, 3.46; P=0.001; Table VI). With regard to overall survival, patients with high HMGA1 expression had a significantly poorer prognosis than those with low HMGA1 expression (P=0.0046; Fig. 1C) . Furthermore, we performed subgroup analysis for submucosal invasive cancer, which can be removed completely by local resection if lymph node metastases do not exist. Lymph node metastasis was observed in 3 out of 10 submucosal invasive cancer cases, and 3 cases with lymph node metastasis had significantly higher HMGA1 mRNA expression than the other 7 cases without lymph node metastasis (P=0.0413; Fig. 1D ). 
Discussion
In the present study, we focused on colorectal cancer (CRC) with metastasis in spite of small size (<2 cm). These cancer cells seem to have a greater ability for invasion and migration. Therefore, we comprehensively analyzed the gene expression profile of these cancer tissues to identify the genes or pathways which regulate the cancer metastasis. Biomarkers for CRC lymph node metastasis have been reported as follows; Grade et al (1) carried out gene expression array analysis on 73 colon cancer tissues and comparative genomic hybridization (CGH) for 32 tumors. They identified 68 genes that were significantly differentially expressed between lymph node-negative and lymph node-positive tumors, the functional annotation of which revealed a preponderance of genes that play a role in cellular immune response and surveillance. Using an in vivo orthotopic CRC model and clinical samples, Hao et al (2) discovered that a five-gene signature [v-yes-1 Yamaguchi sarcoma viral related oncogene homolog (LYN), syndecan binding protein (SDCBP), mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4), dickkopf 1 homolog (DKK1), and midline 1 (MID1)] was closely correlated with lymph node metastasis in CRC. Using proteomics analysis, Meding et al (3) revealed that expression levels of FXYD domain containing ion transport regulator 3 (FXYD3), S100 calcium binding protein A11 (S100A11), and glutathione S-transferase mu 3 (GSTM3) are novel markers for regional lymph node metastasis in colon cancer. In addition, specific signatures associated with tumor stage and lymph node metastases were described (11, 12) .
In the present study, the FXYD5 and S100A genes were significantly regulated in group 1; however, we did not find most of the previously described markers. In the present study, we identified lymph node metastasis-related genes, particularly in small tumors (<20 mm), since we considered that they would be the most informative for clinical applications. This might explain the discrepancy between our results and past reports.
As for the characteristics of the identified genes, we found that anti-apoptotic activity played a key role in cancer metastasis. In general, deregulated cell proliferation together with suppressed apoptosis constitute the minimal common platform upon which tumorigenesis is based (13) . The initial population of malignant cells avoids the apoptotic pathway and then continues to rampantly proliferate. Anti-apoptotic activity must, therefore, be required for cancer cells to form metastases. Notably, genes regulating the epithelial-to-mesenchymal transition related pathways, which have been considered to promote cancer cell invasion and migration (14, 15) , and those regulating cancer stem cell related pathways, which have the potential to initiate and sustain tumor growth and metastasis (16, 17) , did not affect metastatic ability in our study.
We showed that HMGA1 expression has a significant correlation with lymph node metastasis in CRC cases. The high-mobility group (HMG) proteins are low-molecular weight nuclear factors with non-histone chromosomal accessory functions (18) . The A subgroup of HMG interacts with the minor groove of numerous AT-rich promoters and enhancers (19) and plays key roles in chromatin architecture and gene transcription control (19, 20) . Under physiological conditions, HMGA protein expression is high during embryogenesis (21, 22) and decreases to low to undetectable levels in adult tissues. High HMGA expression in adult life is associated only with pathological conditions such as human carcinomas of the thyroid (23, 24) , colon (25) (26) (27) , prostate (28) , pancreas (29) , cervix (30) , ovary (31) and breast (32) . Moreover, large scale gene expression studies show that high expression portends a poor prognosis in some tumors (33, 34) . HMGA1 is also enriched in embryonic stem cells and high grade (poorly Table VI . Univariate and multivariate analysis for lymph node metastasis (logistic regression model).
Univariate analysis
Multivariate analysis differentiated) cancer, including breast, bladder, and brain cancer (34) and is associated with tumor invasion (10, 35) and poorer clinical staging (36) . HMGA1 overexpression induces inactivation of p53's apoptotic function to escape apoptosis in neoplastic transformation (37, 38) and drives stem cell properties in colon cancer cells (39) . In our results, HMGA1 expression level was an indicator of poor prognosis in CRC cases and an independent risk factor for lymph node metastasis. We consider that these results are due to the antiapoptotic function of HMGA1. Intramucosal CRC generally does not metastasize to lymph nodes and is thus a good candidate for endoscopic local resection (40) . By contrast, lymph node metastasis occurs in approximately 6-12% patients with submucosal invasive CRC, which requires surgical resection, including lymph node dissection, for curative treatment (41) (42) (43) (44) . Despite the low possibility of lymph node metastasis in submucosal invasive CRC, surgical resection and removal of regional lymph nodes are considered the standard treatment for this disease (45) . It is noteworthy that tumors with lymph node metastasis had significantly higher HMGA1 expression levels in subgroup analysis for submucosal invasive CRC cases in our results. Perhaps submucosal invasive CRC cases without metastases, which might be cured by endoscopic local resection, could be extracted by HMGA1 expression level. Further studies using a larger number of cases are required.
In conclusion, our data strongly support the clinical significance of HMGA1 expression as a predictive indicator of lymph node metastasis in CRC cases, even in submucosal invasive CRC tumors.
